NasdaqGS - Nasdaq Real Time Price USD

Pacific Biosciences of California, Inc. (PACB)

Compare
1.8250 -0.2150 (-10.54%)
At close: September 20 at 4:00 PM EDT
1.8300 +0.00 (+0.27%)
After hours: September 20 at 7:45 PM EDT
Loading Chart for PACB
DELL
  • Previous Close 2.0400
  • Open 1.9800
  • Bid 1.7900 x 5500
  • Ask 1.8600 x 4500
  • Day's Range 1.7900 - 2.0050
  • 52 Week Range 1.1600 - 10.6500
  • Volume 11,112,150
  • Avg. Volume 9,520,095
  • Market Cap (intraday) 497.365M
  • Beta (5Y Monthly) 2.03
  • PE Ratio (TTM) --
  • EPS (TTM) -1.5000
  • Earnings Date Oct 28, 2024 - Nov 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.83

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

www.pacb.com

796

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PACB

View More

Performance Overview: PACB

Trailing total returns as of 9/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PACB
81.40%
S&P 500
19.55%

1-Year Return

PACB
80.63%
S&P 500
28.32%

3-Year Return

PACB
93.80%
S&P 500
28.64%

5-Year Return

PACB
67.70%
S&P 500
89.66%

Compare To: PACB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PACB

View More

Valuation Measures

Annual
As of 9/20/2024
  • Market Cap

    497.37M

  • Enterprise Value

    912.51M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.57

  • Price/Book (mrq)

    1.01

  • Enterprise Value/Revenue

    4.83

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -211.99%

  • Return on Assets (ttm)

    -11.24%

  • Return on Equity (ttm)

    -70.57%

  • Revenue (ttm)

    188.87M

  • Net Income Avi to Common (ttm)

    -400.38M

  • Diluted EPS (ttm)

    -1.5000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    509.8M

  • Total Debt/Equity (mrq)

    187.73%

  • Levered Free Cash Flow (ttm)

    -297.27M

Research Analysis: PACB

View More

Company Insights: PACB

Research Reports: PACB

View More

People Also Watch